Chemotherapy-Induced Neutropenia (CIN) Therapeutics 'Pipeline Assessment and Market Forecasts to 2018

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Chemotherapy-Induced Neutropenia (CIN) Therapeutics 'Pipeline
Assessment and Market Forecasts to 2018
Published on November 2011

Report Summary

Chemotherapy-Induced Neutropenia (CIN) Therapeutics 'Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Chemotherapy-Induced Neutropenia (CIN) Therapeutics
'Pipeline Assessment and Market Forecasts to 2018'. The report is an essential source of information and analysis on the global CIN
therapeutics market. The report identifies the key trends shaping and driving the global CIN therapeutics market. The report also
provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market
positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the
global CIN sector. This report is built using data and information sourced from proprietary databases, primary and secondary research
and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates that the global Chemotherapy-induced Neutropenia (CIN) therapeutics market was valued at $3.6 billion in
2005 and grew at a Compound Annual Growth Rate (CAGR) of 5.8% to reach $4.8 billion in 2010. The market is forecast to grow at a
CAGR of 2.3% over the next eight years to reach $5.8 billion by 2018. This decline in growth rate is primarily attributed to the
expected patent expiry of Neupogen in 2013 (2006 in Europe) and Neulasta in 2015 which will make way for the entry of biosimilars
(generic version of biologics) into the market. The increase in prescription population will help in partially offsetting the revenue loss
due to the patent expiries.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges of the CIN market. Its scope includes -
- Analysis of seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan), with CIN market revenues data from
2005 to 2010, and forecasts to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by
seven key markets. Pipeline candidates fall under major therapeutic classes such as long acting recombinant PEGylated G-CSFs,
long-acting recombinant human albumin-G-CSFs, long acting glyco-PEGylated recombinant human G-CSFs, long-acting recombinant
GM-CSFs, allogeneic cell-based therapies, recombinant fusion protein G-CSFs, neutrophil stimulators, recombinant protease
inhibitors and hematopoeitic stem cell stimulators.
- Analysis of the current and future competition in the global CIN therapeutics market. Key market players covered are Eurofarma
Laboratorios Ltda, Green Cross Corporation in collaboration with Symyoo, Intas Biopharmaceuticals Ltd. in collaboration with Apotex
Inc. and Teva Pharmaceuticals.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a
qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the CIN
therapeutics market.
- Analysis of key recent licensing and partnership agreements in CIN therapeutics market

Chemotherapy-Induced Neutropenia (CIN) Therapeutics 'Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 1/8


Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by
identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global CIN market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to
impact the global CIN therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of
various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive
advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities
for consolidations, investments and strategic partnerships.
- What's the next big thing in the global CIN therapeutics market landscape' ' Identify, understand and capitalize.

Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 6
2 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Executive Summary 8
2.1 The CIN Therapeutics Market is Forecast to Show Slow Growth Until 2018 8
2.2 The CIN Therapeutics Market has Significant Unmet Need in Terms of Cost-Effectiveness 9
2.3 CIN Developmental Pipeline Lacks Novelty and is Crowded with Biosimilars 10
2.4 Entry of Biosimilars in the CIN Therapeutics Market 11
3 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Introduction 12
3.1 Overview 12
3.1.1 Classification of CIN 16
3.1.2 Febrile Neutropenia 17
3.2 Epidemiology 17
3.3 Symptoms 17
3.4 Etiology 18
3.5 Pathophysiology 18
3.6 Risk factors for CIN 19
3.7 Diagnosis 23
3.8 Treatment of CIN 24
3.9 GlobalData Pipeline Report Guidance 31
4 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Market Characterization 32
4.1 CIN Therapeutics Market Size (2005-2010) ' Global 32
4.2 CIN Therapeutics Market Forecast (2010-2018) ' Global 34
4.3 CIN Therapeutics Market Size (2005-2010) ' The US 36
4.4 CIN Therapeutics Market Forecast (2010-2018) ' The US 37
4.5 CIN Therapeutics Market Size (2005-2010) ' France 38
4.6 CIN Therapeutics Market Forecast (2010-2018) ' France 41



4.7 CIN Therapeutics Market Size (2005-2010) ' Germany 43
4.8 CIN Therapeutics Market Forecast (2010-2018) ' Germany 45
4.9 CIN Therapeutics Market Size (2005-2010) ' Italy 47
4.10 CIN Therapeutics Market Forecast (2010-2018) ' Italy 49
4.11 CIN Therapeutics Market Size (2005-2010) ' Spain 51
4.12 CIN Therapeutics Market Forecast (2010-2018) ' Spain 53
4.13 CIN Therapeutics Market Size (2005-2010) ' The UK 55
4.14 CIN Therapeutics Market Forecast (2010-2018) ' The UK 57
4.15 CIN Therapeutics Market Size (2005-2010) ' Japan 59
4.16 CIN Therapeutics Market Forecast (2010-2018) ' Japan 60
4.17 Drivers and Barriers for the CIN Therapeutics Market 62
4.17.1 Drivers for the CIN Therapeutics Market 62
4.17.2 Barriers for the CIN Therapeutics Market 63
4.18 Key Events Impacting the Future Market 64
4.19 Opportunity and Unmet Need Analysis 64
4.19.1 Key Takeaway 66
5 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Competitive Assessment 68
5.1 Overview 68
5.2 Strategic Competitor Assessment 68
5.2 Product Profile for the Major Marketed Products in the CIN Therapeutics Market 70
5.2.1 Neulasta (pegfilgrastim) 70
5.2.2 Neupogen (filgrastim) 71
5.2.3 Leukine (sargramostim) 72
5.2.4 Granocyte/ Neutrogin (lenograstim) 73
5.3 Key Takeaway 75
6 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Pipeline Assessment 76
6.1 Overview 76
6.2 Strategic Pipeline Assessment 76
6.2.1 CIN Therapeutics ' Pre-registration Pipeline 77
6.2.2 CIN Therapeutics ' Phase III Pipeline 77
6.2.3 CIN Therapeutics ' Phase II Pipeline 78
6.2.4 CIN Therapeutics ' Phase I/II Pipeline 78
6.2.5 CIN Therapeutics ' Phase I Pipeline 78
6.2.6 CIN Therapeutics ' Preclinical Pipeline 78
6.3 CIN Therapeutics ' Pipeline by Mechanism of Action 79
6.4 CIN Technology Trends Analytical Framework 80
6.5 Molecule Profile for Promising Drugs under Clinical Development 81
6.5.1 Neugranin 81
6.5.2 Lipegfilgrastim (XM22) 82
6.5.3 Filgrastim 82
6.5.4 Neukine 82
6.5.5 GCPGC 83
6.6 Key takeaway 83
7 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Clinical Trials Mapping 84
7.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 84
7.2 Clinical Trials by Phase 85
7.3 Clinical Trials by Status 86
7.4 Overall Sponsors 86



7.5 Prominent Sponsors 87
7.6 Participants in Therapeutic Clinical Trials ' Companies 88
8 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Strategic Assessment 90
8.1 CIN Therapeutics: Implications for Future Market Competition 90
9 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Future Players 93
9.1 Introduction 93
9.2 Company Profiles 93
9.2.1 Teva Pharmaceutical Industries Limited 93
9.2.2 Eurofarma Laboratorios Ltda. 95
9.2.3 Green Cross Corporation 96
9.2.4 Intas Biopharmaceuticals Ltd. 96
9.2.5 Apotex Inc. 97
10 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Appendix 99
10.1 Definitions 99
10.2 Acronyms 99
10.3 Research Methodology 100
10.3.1 Coverage 101
10.3.2 Secondary Research 101
10.3.3 Forecasting 101
10.3.4 Primary Research 104
10.3.5 Expert Panel Validation 105
10.4 Contact Us 105
10.5 Disclaimer 105
10.6 Bibliography 106

List of Tables

Table 1: CIN Therapeutics Market, Global, Forecast ($m), 2005'2010 34
Table 2: CIN Therapeutics Market, Global, Forecast ($m), 2010'2018 36
Table 3: CIN Therapeutics Market, The US, Revenue ($m), 2005'2010 38
Table 4: CIN Therapeutics Market, The US, Forecast ($m), 2010'2018 39
Table 5: CIN Therapeutics Market, France, Revenue ($m), 2005'2010 41
Table 6: CIN Therapeutics Market, France, Forecast ($m), 2010'2018 43
Table 7: CIN Therapeutics Market, Germany, Revenue ($m), 2005'2010 45
Table 8: CIN Therapeutics Market, Germany, Forecast ($m), 2010'2018 47
Table 9: CIN Therapeutics Market, Italy, Revenue ($m), 2005'2010 49
Table 10: CIN Therapeutics Market, Italy, Forecast ($m), 2010'2018 51
Table 11: CIN Therapeutics Market, Spain, Revenue ($m), 2005'2010 53
Table 12: CIN Therapeutics Market, Spain, Forecast ($m), 2010'2018 55
Table 13: CIN Therapeutics Market, The UK, Revenue ($m), 2005'2010 57
Table 14: CIN Therapeutics Market, The UK, Forecast ($m), 2010'2018 59
Table 15: CIN Therapeutics Market, Japan, Revenue ($m), 2005'2010 60
Table 16: CIN Therapeutics Market, Japan, Forecast ($m), 2010'2018 62
Table 17: CIN Market, Global, Major Marketed Products Comparison, 2011 75
Table 18: CIN Therapeutics ' Pre-registration Pipeline, 2011 78
Table 19: CIN Therapeutics ' Phase III Pipeline, 2011 78
Table 20: CIN Therapeutics ' Phase II Pipeline, 2011 79
Table 21: CIN Therapeutics ' Phase I/II Pipeline, 2011 79



Table 22: CIN Therapeutics ' Phase I Pipeline, 2011 79
Table 23: CIN Therapeutics ' Preclinical Pipeline, 2011 79
Table 24: CIN Therapeutics ' Clinical Trials by Country, 2011 85
Table 25: CIN Therapeutics ' Clinical Trials by Phase, 2011 86
Table 26: CIN Therapeutics ' Clinical Trials by Status (%), 2011 87
Table 27: CIN Therapeutics ' Overall Sponsors (%), 2011 88
Table 28: CIN Therapeutics ' Prominent Sponsors, 2011 89
Table 29: CIN Therapeutics ' Top Companies Participating in Therapeutics Clinical Trials, 2011 90
Table 30: Teva Pharmaceuticals- Hematological Disorders Pipeline, 2011 95
Table 31: Teva Pharmaceuticals- CIN Pipeline, 2011 96
Table 32: Eurofarma Laboratorios Ltda., CIN Pipeline, 2011 96
Table 33: Green Cross Corporation, Hematological Disorders Pipeline, 2011 97
Table 34: Green Cross Corporation, CIN Pipeline, 2011 97
Table 35: Intas Biopharmaceuticals Ltd., CIN Pipeline, 2011 98
Table 36: Apotex Inc., CIN Pipeline, 2011 99

List of Figures

Figure 1: CIN Therapeutics Market, Global, Revenue and Forecasts ($bn), 2005'2018 9
Figure 2: CIN Therapeutics, Opportunity and Unmet Need, 2011 10
Figure 3: CIN Therapeutics, Hematopoesis ' Formation and Development of Blood Cells 13
Figure 4: CIN Therapeutics, Risk of Neutropenic Complications in the First Cycle of Chemotherapy 14
Figure 5: CIN Therapeutics, The Course of Neutropenic Complications 15
Figure 6: CIN Therapeutics, CIN Grading by National Cancer Institute 16
Figure 7: CIN Therapeutics, Risk of Neutropenic Complications in the First Cycle of Chemotherapy by Tumor Type 20
Figure 8: CIN Therapeutics, Chemotherapy Regimens with a High (>20%) Febrile Neutropenia Risk 22
Figure 9: CIN Therapeutics, Bone Marrow Aspiration and Biopsy 23
Figure 10: CIN Therapeutics, Marketed Drugs 26
Figure 11: CIN Therapeutics, Risks and Benefits of CSF Use 27
Figure 12: CIN Therapeutics, Alignment of Recommendations for the Prophylactic Use of G-CSFs 29
Figure 13: CIN Therapeutics, NCCN ' Decision Tree for Primary Prophylaxis 30
Figure 14: CIN Therapeutics, NCCN Guidelines for Treatment 31
Figure 15: CIN Therapeutics Market, Global, Revenue ($m), 2005'2010 33
Figure 16: CIN Therapeutics Market, Global, Forecast ($m), 2010'2018 36
Figure 17: CIN Therapeutics Market, the US, Revenue ($m), 2005'2010 37
Figure 18: CIN Therapeutics Market, The US, Forecast ($m), 2010'2018 38
Figure 19: CIN Therapeutics Market, France, Revenue ($m), 2005'2010 40
Figure 20: CIN Therapeutics Market, France, Forecast ($m), 2010'2018 42
Figure 21: CIN Therapeutics Market, Germany, Revenue ($m), 2005'2010 44
Figure 22: CIN Therapeutics Market, Germany, Forecast ($m), 2010'2018 46
Figure 23: CIN Therapeutics Market, Italy, Revenue ($m), 2005'2010 48
Figure 24: CIN Therapeutics Market, Italy, Forecast ($m), 2010'2018 51
Figure 25: CIN Therapeutics Market, Spain, Revenue ($m), 2005'2010 52
Figure 26: CIN Therapeutics Market, Spain, Forecast ($m), 2010'2018 54
Figure 27: CIN Therapeutics Market, The UK, Revenue ($m), 2005'2010 56
Figure 28: CIN Therapeutics Market, The UK, Forecast ($m), 2010'2018 58
Figure 29: CIN Therapeutics Market, Japan, Revenue ($m), 2005'2010 60
Figure 30: CIN Therapeutics Market, Japan, Forecast ($m), 2010'2018 62



Figure 31: CIN Therapeutics Market, Drivers and Restraints, 2011 65
Figure 32: CIN Therapeutics, Opportunity and Unmet Need, 2011 66
Figure 33: CIN Therapeutics ' Strategic Competitor Assessment, 2011 69
Figure 34: CIN Therapeutics ' Pipeline by Phase of Clinical Development, 2011 78
Figure 35: CIN Therapeutics ' Clinical Pipeline by Mechanism Of Action, 2011 80
Figure 36: CIN Therapeutics, Technology Trends Analytical Framework, , 2011 81
Figure 37: CIN Therapeutics, Technology Trends Analytical Framework, Description, 2011 82
Figure 38: CIN Therapeutics ' Clinical Trials by Country, 2011 85
Figure 39: CIN Therapeutics ' Clinical Trials by Phase (%), 2011 86
Figure 40: CIN Therapeutics ' Clinical Trials by Status (%), 2011 87
Figure 41: CIN Therapeutics ' Overall Sponsors (%), 2011 88
Figure 42: CIN Therapeutics ' Prominent Sponsors (%), 2011 89
Figure 43: CIN Therapeutics Market, Implications for Future Market Competition, 2011 91
Figure 44: CIN Therapeutics ' Pipeline by Company, 2011 93
Figure 45: GlobalData Market Forecasting Model 104Teva Pharmaceutical Industries Limited
Eurofarma Laboratorios Ltda.
Green Cross Corporation
Intas Biopharmaceuticals Ltd.
Apotex Inc.


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Chemotherapy-Induced Neutropenia (CIN) Therapeutics 'Pipeline Assessment and Market Forecasts to 2018

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 3 500.00 Quantity: _____

Site License--USD 7 000.00 Quantity: _____

Corporate License--USD 10 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Chemotherapy-Induced Neutropenia (CIN) Therapeutics 'Pipeline Assessment and Market Forecasts to 2018

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Chemotherapy-Induced Neutropenia (CIN) Therapeutics 'Pipeline Assessment and Market Forecasts to 2018